Joshua Weinger

Preliminary Injunction Denied Against Amgen In Aflibercept BPCIA Litigation

Recent PTAB Developments For Regeneron's Aflibercept-Dosing Patents

Court Cancels Injunction Hearings In Aflibercept BPCIA Litigation; Regeneron May Seek Temporary Restraining Orders

Goodwin Releases Update To Its Comprehensive Guide To Biosimilars Litigation And Regulation In The U.S.

Breaking: Judgment In Regeneron v. Mylan (Aflibercept) BPCIA Case Finding Some Claims Of Asserted Patents Valid And Infringed

Formycon Announces FDA Acceptance Of The ABLA For Its Aflibercept Biosimilar

Amgen Intervenes In Regeneron V. Mylan BPCIA Aflibercept Litigation To Seek Public Access To Sealed Documents

New Patents Listed In The Purple Book For Regeneron's EYLEA

Regeneron V. Mylan BPCIA Aflibercept Litigation Update: Claim Construction Order And Stipulation To Narrow The Case For June 2023 Trial

Regeneron V. Mylan – Update On Aflibercept BPCIA Litigation